trending Market Intelligence /marketintelligence/en/news-insights/trending/5076y6P6WZCYZJ151_UGWg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UK regulator recommends Novartis' lung cancer, AbbVie's hepatitis C drugs

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


UK regulator recommends Novartis' lung cancer, AbbVie's hepatitis C drugs

The U.K.'s National Institute for Health and Care Excellence recommended Novartis AG's Zykadia as a treatment option within the National Health Service for adults with untreated ALK-positive non-small cell lung cancer.

NICE said Zykadia, or ceritinib, is only recommended if the Swiss drugmaker provides it with the undisclosed discount agreed in the patient access scheme.

Although the clinical study for Zykadia is not yet complete, the therapy was found to be more effective than chemotherapy in increasing the length of time people live without disease progression.

The British regulator had recommended the drug as an option for previously treated ALK-positive lung cancer patients.

Additionally, NICE recommended AbbVie Inc.'s Maviret for treating chronic hepatitis C.

The treatment, also known as glecaprevir plus pibrentasvir, is an additional option suitable for all genotypes, with or without scarring of the liver, and in people who are untreated or have been treated before with interferon-based treatment.

Clinical trials show that the drug is effective for treating chronic hepatitis C across all genotypes, the watchdog noted.

Earlier in 2017, NICE recommended Gilead Sciences Inc.'s Epclusa, or sofosbuvir plus velpatasvir, as a treatment option for all genotypes of chronic hepatitis C.